TECHNICAL ANALYSIS

[stocksurgeon]

APNS- (.07x.075) 817k vol - Applied NeuroSolutions, Inc. (APNS) is a development stage biopharmaceutical company focused on diagnostics and therapeutics for the treatment of Alzheimer’s Disease (AD).

Applied NeuroSolutions’ has a long-term agreement with Albert Einstein College of Medicine (AECOM) that grants APNS the exclusive licensing rights to commercialize Dr. Peter Davies’ neurodegenerative disease related discoveries. The technologies are based on the presence of an abnormal form of a protein present in the brains and cerebrospinal fluid (CSF) of AD patients. A specific chemical change in this protein, known as tau, results in an abnormal protein called ptau-231 (tau protein phosphorylated on amino acid 231). The presence of the ptau-231 protein leads to the development of abnormal structures (paired helical filaments and neurofibrillary tangles – the hallmark of Alzheimer’s disease) that contribute to nerve cell death. The correlation between excess amounts of the ptau-231 protein and AD supports the development of diagnostic tests, in vitro drug discovery systems and therapeutics aimed at preventing the formation of this protein and the accompanying neuron-destroying structures. The Company’s technology originated from Dr. Peter Davies, the Judith and Burton P. Resnick Professor of Alzheimer’s Disease Research at the Albert Einstein College of Medicine, and APNS’ scientific founder.